NCT00242996View on ClinicalTrials.gov

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Lymphoma

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

rituximab

BIOLOGICAL

sargramostim

DRUG

carmustine

DRUG

cyclophosphamide

DRUG

etoposide

PROCEDURE

adjuvant therapy

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00242996 - Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter